Related Experiment Video
Updated: Jul 2, 2026
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
CCR5 as target for HIV-1 gene therapy
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 3E2, Canada.
Current Gene Therapy
|August 12, 2008
Summary
Targeting the CCR5 co-receptor offers a promising strategy to combat HIV-1 infection and transmission. Gene therapy approaches aim to downregulate CCR5, preventing viral entry without apparent immune defects.
Area of Science:
- Immunology
- Virology
- Genetics
Background:
- Human immunodeficiency virus type-1 (HIV-1) causes acquired immune deficiency syndrome (AIDS).
- Viral entry depends on the envelope glycoprotein binding to CD4 and a co-receptor (CCR5 or CXCR4).
- CCR5 is crucial for HIV-1 infection and disease progression.
Purpose of the Study:
- To review the significance of targeting the CCR5 co-receptor for HIV-1 therapy.
- To summarize current gene therapy strategies for CCR5 downregulation.
Main Methods:
- Review of existing literature on CCR5 as an HIV-1 therapeutic target.
- Analysis of various anti-CCR5 molecules and gene therapy approaches.
- Comparison of CCR5 with other potential targets like CD4 and CXCR4.
Main Results:
- CCR5 is a viable therapeutic target due to its essential role in HIV-1 entry and lack of essential immune function.
- Individuals lacking functional CCR5 show reduced HIV-1 susceptibility and delayed AIDS progression.
- Diverse strategies, including small molecules, antibodies, and gene therapies, are being developed to block CCR5.
Conclusions:
- Targeting CCR5 is a promising strategy to prevent HIV-1 infection and transmission.
- Gene therapy offers innovative methods to downregulate CCR5 expression or synthesis.
- Further development of anti-CCR5 strategies holds potential for effective HIV-1 intervention.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:28CRISPR/Cas9 Genome Editing
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...